Noradrenaline Should Be Preferred Over Metaraminol for Vasopressor Support in Critically Ill Patients
Noradrenaline (norepinephrine) is the evidence-based first-line vasopressor for shock states and should be used instead of metaraminol, which lacks robust safety and efficacy data despite widespread use in some regions. 1
Key Advantages of Noradrenaline
Guideline-Supported First-Line Agent
Major international guidelines explicitly recommend noradrenaline as the first-line vasopressor for patients with hypotension or shock 2. This recommendation is based on extensive clinical evidence and established safety profiles. In contrast, metaraminol has no guideline support and is used primarily based on local practice patterns rather than evidence 2.
Superior Evidence Base
Noradrenaline has decades of high-quality research demonstrating its cardiovascular effects, including:
Metaraminol has remarkably limited evidence:
Renal Protection Considerations
Recent high-quality animal studies reveal important differences in kidney effects:
- Metaraminol demonstrated significantly better renal outcomes in septic shock models, with lower creatinine levels at 3 hours compared to noradrenaline 4
- However, noradrenaline worsened renal medullary tissue oxygenation during cardiopulmonary bypass compared to vasopressin, though this was in a specific surgical context 5
Clinical caveat: While metaraminol may have theoretical renal advantages in animal models, this cannot override the lack of human safety data and guideline support. The renal findings require validation in human trials before changing practice.
Dosing Predictability
A major practical disadvantage of metaraminol is highly variable dose equivalence:
- The median conversion ratio is approximately 12.5:1 (metaraminol:noradrenaline) 6
- However, the coefficient of variation is 77% with significant individual variability 6
- Only 50% of variation in noradrenaline dose can be predicted from metaraminol dose 6
- One in five patients experience MAP drops >10 mmHg during transition from metaraminol to noradrenaline 6
This unpredictability creates risk during transitions and makes titration less reliable.
Cardiac Effects
Noradrenaline has well-characterized cardiac effects with direct positive chronotropic effects typically counterbalanced by vagal reflex activity from increased blood pressure 1. Metaraminol's cardiac effects are less well-studied in critically ill populations, though it appears not to increase heart rate in septic shock models 4.
Common Pitfalls to Avoid
- Do not use metaraminol as a substitute for noradrenaline in shock states simply because it's locally available or familiar
- Avoid assuming dose equivalence when transitioning between agents—expect significant variability and monitor closely 6
- Do not extrapolate animal renal data to justify metaraminol use over guideline-recommended noradrenaline
- Recognize that metaraminol use in obstetric anesthesia for spinal-induced hypotension (where it shows non-inferiority 7) does not translate to appropriateness in septic shock or other critical illness
Clinical Algorithm
For vasopressor selection in shock:
- Start with noradrenaline as first-line agent 1, 2
- Titrate to MAP ≥65 mmHg
- If transitioning from metaraminol (inherited from another setting), expect 12.5:1 conversion ratio but monitor for hypotension 6
- Consider adding vasopressin or other agents per guidelines rather than substituting metaraminol
The only exception: Low-risk obstetric patients undergoing cesarean delivery, where metaraminol at 2.00 μg/kg/min shows non-inferiority to noradrenaline for preventing spinal anesthesia-induced hypotension 7.